Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited disorder that affects 1 to 2 individuals per 1000 worldwide. Morphological disorganization of renal tissue results in the hallmark disease process: development of large, fluid-filled cysts in the kidney, which over time increase kidney size and ultimately compromise kidney function. These changes typically begin insidiously, with few symptoms to alert patients that the damage is occurring. Patients exhibit urine concentration, pain, hypertension, kidney stones, hematuria, and infections; long-term sequelae include end-stage renal disease (ESRD) and cardiovascular complications, with 70% of patients developing ESRD at a median age of 58 years.
In this video, 2 experts in the management of ADPKD discuss the gamut of concerns in the management of ADPKD, from deciding which patients should be screened for ADPKD, how to identify patients at increased risk for severe disease and/or complications including extrarenal manifestations of ADPKD, and current standards of care to the role of new and emerging treatments that can delay the progression of ADPKD.